Format

Send to

Choose Destination
Blood. 2014 Nov 13;124(20):3092-100. doi: 10.1182/blood-2014-04-566687. Epub 2014 Sep 5.

JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.

Author information

1
Vlaams Instituut voor Biotechnologie Center for the Biology of the Disease, Leuven, Belgium; Katholieke Universiteit Leuven Center for Human Genetics, Leuven, Belgium;
2
Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;
3
Katholieke Universiteit Leuven Center for Human Genetics, Leuven, Belgium;
4
Department of Pediatric Oncology/Hematology, Erasmus University Medical Center Rotterdam-Sophia Children's Hospital, Rotterdam, The Netherlands; and.
5
Department of Pathology, Universitaire Ziekenhuizen, Leuven, Belgium.

Abstract

JAK3 is a tyrosine kinase that associates with the common γ chain of cytokine receptors and is recurrently mutated in T-cell acute lymphoblastic leukemia (T-ALL). We tested the transforming properties of JAK3 pseudokinase and kinase domain mutants using in vitro and in vivo assays. Most, but not all, JAK3 mutants transformed cytokine-dependent Ba/F3 or MOHITO cell lines to cytokine-independent proliferation. JAK3 pseudokinase mutants were dependent on Jak1 kinase activity for cellular transformation, whereas the JAK3 kinase domain mutant could transform cells in a Jak1 kinase-independent manner. Reconstitution of the IL7 receptor signaling complex in 293T cells showed that JAK3 mutants required receptor binding to mediate downstream STAT5 phosphorylation. Mice transplanted with bone marrow progenitor cells expressing JAK3 mutants developed a long-latency transplantable T-ALL-like disease, characterized by an accumulation of immature CD8(+) T cells. In vivo treatment of leukemic mice with the JAK3 selective inhibitor tofacitinib reduced the white blood cell count and caused leukemic cell apoptosis. Our data show that JAK3 mutations are drivers of T-ALL and require the cytokine receptor complex for transformation. These results warrant further investigation of JAK1/JAK3 inhibitors for the treatment of T-ALL.

Comment in

PMID:
25193870
DOI:
10.1182/blood-2014-04-566687
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center